Rapid diagnosis of mild cognitive impairment and depression in seniors
The Proactive Screening and Diagnosis of Mild Cognitive Impairment and Depression in Patients Ages 60 and Over: An Implementation Study
This study is testing a new way to quickly and accurately diagnose mild cognitive impairment and depression in seniors aged 60 and older to help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 960 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Miro Health Academic / other |
| Locations | 2 sites (Sacramento, California and 1 other locations) |
| Trial ID | NCT06011681 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the accuracy of diagnosing mild cognitive impairment (MCI) and late-life depression (LLD) in individuals aged 60 and over. By utilizing advanced artificial intelligence developed by Miro Health, the study seeks to differentiate between MCI and LLD, which are common in the aging population. The focus is on refining diagnostic tools to improve patient outcomes and inform future treatment strategies. Participants will be evaluated based on specific criteria related to their cognitive and emotional health.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 60 and over who have been diagnosed with mild cognitive impairment or late-life depression.
Not a fit: Patients younger than 60 or those with unresolved neurological or psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of MCI and depression, improving the quality of life for older adults.
How similar studies have performed: Other studies have shown promise in using AI for diagnosing cognitive impairments, suggesting that this approach could be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * LLD: Age 60 or over; diagnosis of LLD or symptoms consonant with LLD; PHQ-9 score from 15 to 27 * MCI: Age 60 or over; diagnosis of MCI or self-reported insidious onset and continued worsening of cognitive decline; intact activities of daily living * HC: Age 60 or over Exclusion Criteria: * Age 59 or younger; history of unresolved neurological or psychiatric conditions; current medications known to affect cognition; history of substance abuse; unable to perform activities of daily living; change in employment status due to condition
Where this trial is running
Sacramento, California and 1 other locations
- Miro Health — Sacramento, California, United States (Recruiting)
- Miro Health — Miami, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Shenly Glenn, BS — Miro Health
- Study coordinator: Shenly Glenn
- Email: shenly@mirohealth.com
- Phone: 415-300-0533
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.